Cargando…
Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy
This study aimed to identify factors that predict prognosis after radiotherapy for brain metastases (BMs) from small-cell lung cancer (SCLC). This study retrospectively evaluated 48 consecutive patients who underwent whole-brain radiotherapy (WBRT) for BMs from SCLC between February 2008 and Decembe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430245/ https://www.ncbi.nlm.nih.gov/pubmed/30576550 http://dx.doi.org/10.1093/jrr/rry107 |
_version_ | 1783405746296193024 |
---|---|
author | Anami, Shimpei Doi, Hiroshi Nakamatsu, Kiyoshi Uehara, Takuya Wada, Yutaro Fukuda, Kohei Inada, Masahiro Ishikawa, Kazuki Kanamori, Shuichi Nishimura, Yasumasa |
author_facet | Anami, Shimpei Doi, Hiroshi Nakamatsu, Kiyoshi Uehara, Takuya Wada, Yutaro Fukuda, Kohei Inada, Masahiro Ishikawa, Kazuki Kanamori, Shuichi Nishimura, Yasumasa |
author_sort | Anami, Shimpei |
collection | PubMed |
description | This study aimed to identify factors that predict prognosis after radiotherapy for brain metastases (BMs) from small-cell lung cancer (SCLC). This study retrospectively evaluated 48 consecutive patients who underwent whole-brain radiotherapy (WBRT) for BMs from SCLC between February 2008 and December 2017. WBRT was delivered at a median dose of 30 Gy (range: 30–40 Gy) in 10 fractions (range: 10–16 fractions). Clinical factors were tested for associations with overall survival after WBRT. The median survival and 1-year overall survival rate after WBRT treatment were 232 days and 34.4%, respectively. Univariate analyses revealed that longer survival was associated with Eastern Cooperative Oncology Group performance status of 0–1, asymptomatic BMs, lactate dehydrogenase (LDH) in the normal range, Radiation Therapy Oncology Group–recursive partitioning analysis class 2, and a graded prognostic assessment score of ≥1.5 (P < 0.01, P < 0.01, P < 0.01, P < 0.01 and P < 0.05, respectively). In the multivariate analyses, longer survival was independently associated with asymptomatic BMs [hazard ratio for death (HR), 0.32; 95% confidence interval (CI), 0.12–0.79; P < 0.05] and LDH in the normal range (HR, 0.42; 95% CI, 0.21–0.83; P < 0.05). The presence of symptoms due to BMs and LDH values independently predicted prognosis after WBRT for BMs from SCLC. Elevated LDH may provide valuable information for identifying patients with BMs who could have poor survival outcomes. |
format | Online Article Text |
id | pubmed-6430245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64302452019-03-26 Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy Anami, Shimpei Doi, Hiroshi Nakamatsu, Kiyoshi Uehara, Takuya Wada, Yutaro Fukuda, Kohei Inada, Masahiro Ishikawa, Kazuki Kanamori, Shuichi Nishimura, Yasumasa J Radiat Res Regular Paper This study aimed to identify factors that predict prognosis after radiotherapy for brain metastases (BMs) from small-cell lung cancer (SCLC). This study retrospectively evaluated 48 consecutive patients who underwent whole-brain radiotherapy (WBRT) for BMs from SCLC between February 2008 and December 2017. WBRT was delivered at a median dose of 30 Gy (range: 30–40 Gy) in 10 fractions (range: 10–16 fractions). Clinical factors were tested for associations with overall survival after WBRT. The median survival and 1-year overall survival rate after WBRT treatment were 232 days and 34.4%, respectively. Univariate analyses revealed that longer survival was associated with Eastern Cooperative Oncology Group performance status of 0–1, asymptomatic BMs, lactate dehydrogenase (LDH) in the normal range, Radiation Therapy Oncology Group–recursive partitioning analysis class 2, and a graded prognostic assessment score of ≥1.5 (P < 0.01, P < 0.01, P < 0.01, P < 0.01 and P < 0.05, respectively). In the multivariate analyses, longer survival was independently associated with asymptomatic BMs [hazard ratio for death (HR), 0.32; 95% confidence interval (CI), 0.12–0.79; P < 0.05] and LDH in the normal range (HR, 0.42; 95% CI, 0.21–0.83; P < 0.05). The presence of symptoms due to BMs and LDH values independently predicted prognosis after WBRT for BMs from SCLC. Elevated LDH may provide valuable information for identifying patients with BMs who could have poor survival outcomes. Oxford University Press 2019-03 2018-12-20 /pmc/articles/PMC6430245/ /pubmed/30576550 http://dx.doi.org/10.1093/jrr/rry107 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial reuse, please contact journals.permissions@oup.com |
spellingShingle | Regular Paper Anami, Shimpei Doi, Hiroshi Nakamatsu, Kiyoshi Uehara, Takuya Wada, Yutaro Fukuda, Kohei Inada, Masahiro Ishikawa, Kazuki Kanamori, Shuichi Nishimura, Yasumasa Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy |
title | Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy |
title_full | Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy |
title_fullStr | Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy |
title_full_unstemmed | Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy |
title_short | Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy |
title_sort | serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy |
topic | Regular Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430245/ https://www.ncbi.nlm.nih.gov/pubmed/30576550 http://dx.doi.org/10.1093/jrr/rry107 |
work_keys_str_mv | AT anamishimpei serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy AT doihiroshi serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy AT nakamatsukiyoshi serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy AT ueharatakuya serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy AT wadayutaro serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy AT fukudakohei serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy AT inadamasahiro serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy AT ishikawakazuki serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy AT kanamorishuichi serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy AT nishimurayasumasa serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy |